Signals, Powered By EquityPandit
Cipla has received approval for Q-TIB, a combination drug which is suggested to help prevent tuberculosis infection in people with HIV, from the World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet.
As per Cipla, it will market the product globally, and it is for the first time that such a combination has been made available in the world.
Further, Q-TIB will help in preventing TB infection in people living with HIV, as they are more prone to infections, due to weak immune system.
